🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tomorrow, our CEO, Robert Ang will discuss #VorBio’s novel platform combining HSC biology, genome engineering, and targeted therapies in a fireside chat at the H.C. Wainwright & Co. 2nd Annual Cell Therapy Virtual Conference. Learn more: buff.ly/3Vxcpz1

Tomorrow, our CFO, Nathan Jorgensen, PhD, will present #VorBio’s innovative approach that combines gene-edited HSCs with targeted therapies to potentially bring a cure to patients with #AML at the Needham Virtual Healthcare Conference. Learn more: buff.ly/3Vxcpz1

Next week, members of our leadership team will discuss the advantages of #VorBio’s in-house clinical manufacturing facility & participate in a panel at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit. View the webcast at: buff.ly/3PbDJhl #ChardanGMConf

We are thrilled to welcome Fouad Namouni, MD, to our Board of Directors. Dr. Namouni’s deep oncology and cancer immunotherapy drug expertise will be invaluable to #VorBio as we continue to advance our novel approach to curing #AML. Learn more: buff.ly/3ycZOXO

Today, we announced our Q1 results and provided a corporate update. Read our press release here: tinyurl.com/bdepp4hs

Tomorrow, members of #VorBio leadership will participate in a fireside chat at The Citizens JMP Life Sciences Conference to discuss #VorBio’s novel platform that aims to transform the standard of care for #bloodcancers. Watch the webcast at: buff.ly/3PbDJhl

Next week, our CEO, Robert Ang, will discuss #VorBio’s innovative approach to #bloodcancer treatment in a fireside chat at the H.C. Wainwright & Co. 2nd Annual BioConnect Investor Conference. Learn more: buff.ly/3K9oVNW

Today, we announced our Q2 results and provided a corporate update. Read our press release here: buff.ly/4ch5bUn

We are excited to share new VBP101 clinical data that validates our approach of using shielded transplants to deliver targeted therapies, encouraging VCAR33 (ALLO) data and a new asset, VADC45. We will host an investor call today at 4:30pm ET. Read more: buff.ly/4ecLmyV

Today, our CEO Robert Ang is attending and participating in investor meetings at the Morgan Stanley 22nd Annual Global Healthcare Conference. Learn more about #VorBio: ir.vorbio.com/static-files/1…

Next week, #VorBio will discuss its novel approach combining shielded transplants with targeted therapies to treat #AML in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference. Learn more: ir.vorbio.com/static-files/1… #ChardanGMConf

We are excited to welcome Han Choi, MD, LLM as #VorBio’s CFO. Han’s extensive experience in healthcare investment and strategic operations will help our team advance our mission of transforming outcomes for patients with AML & other blood cancers. ir.vorbio.com/news-releases/…

Today, we announced our Q3 results and provided a corporate update. Read our press release here: ir.vorbio.com/news-releases/…

We’re looking forward to presenting our research and clinical data at #ASH24! We will publish posters and presentations on our website as embargoes are lifted so stay tuned! You can find them in our publications library: vorbio.com/publications/

Yesterday, at hashtag#ASH24, we presented data further validating our approach of using shielded transplants to deliver targeted therapies. We will host an analyst and investor call today at 8:00am ET. Read more in our press release here: lnkd.in/e59X23PC

We are pleased to announce that we have entered into a securities purchase agreement for a private investment in public equity financing (PIPE) that is expected to result in gross proceeds of approximately $55.6 million. Read more here: bit.ly/3VVufLe

We are thrilled to welcome Erez Kalir to our Board of Directors. Mr. Kalir’s extensive experience in the biotech sector and his track record of fostering innovation will be invaluable as we advance our vision to revolutionize blood cancer treatment: ir.vorbio.com/news-releases/…

Today, members of our management team will discuss #VorBio’s novel approach to that aims to transform treatments for #AML in a fireside chat at the Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference. View the webcast at: wsw.com/webcast/oppenh…

Today, we announced our Q4 results and provided a corporate update. Read our press release here: ir.vorbio.com/news-releases/…

Vor Bio shares key updates: 🔹Global ex-China license for telitacicept (late-stage novel autoimmune therapy) 🔹Seasoned biopharma leader Jean-Paul Kress, MD appointed CEO & Chairman 🔹A $175 million PIPE financing Read More: ir.vorbio.com/news-releases/